Save on Brolucizumab-DBLL with Coupons, Discounts & Savings Programs

Brolucizumab-DBLL is available as a 6 mg/0.05 mL solution in a single-dose pre-filled syringe or vial.

Brolucizumab-DBLL is an injection into the back space of the eye to help treat wet age-related macular degeneration (wet AMD).

Brolucizumab-DBLL is a VEGF inhibitor. This means it blocks VEGF, which helps slow the growth of abnormal blood vessels.

Brolucizumab-DBLL is usually given by your eye specialist (ophthalmologist) either in their office or another healthcare setting. In general, you’ll get a 6 mg dose injected into the back of your eye once every month for the first 3 months. Then, you’ll only need a 6 mg dose once every 2 to 3 months.

Brolucizumab-DBLL is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. You should not use this medication if any of the following apply:

• Ocular or Periocular Infections
• Active Intraocular Inflammation Hypersensitivity

Common side effects of Brolucizumab-DBLL:

• Blurry vision
• Cataract
• Red patch on the eye
• Eye floaters
• Eye pain
• Eye inflammation
• Greater pressure in the eye
• Abnormal bleeding in the eye

Serious side effects are rare with Brolucizumab-DBLL. Contact your healthcare provider immediately if you experience any of the following.

• Retinal detachment: flashing lights, shadow or dark curtain across your field of vision, vision loss
• Unusual changes in your vision

There are no major drug interactions listed for Brolucizumab-DBLL. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking.

Various FDA-approved generic manufacturers

Based on the anti-VEGF mechanism of action for brolucizumab, treatment with Brolucizumab-DBLL may pose a risk to human embryo-fetal development. Brolucizumab-DBLL should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. Females of reproductive potential should use highly effective contraception (methods that result in less than 1% pregnancy
rates) during treatment with Brolucizumab-DBLL and for at least one month after the last dose when stopping treatment with Brolucizumab-DBLL.

• Beovu